ProCE Banner Activity

ELEVATE-TN: 5-Yr Update of Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL

Slideset Download
Conference Coverage
After a median follow-up of approximately 5 years, acalabrutinib-based combination therapy and monotherapy maintained significantly improved PFS vs chemoimmunotherapy in patients with treatment-naive CLL with no new safety concerns.

Released: June 07, 2022

Expiration: June 06, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab